Reversal of Metabolic Deficits by Lipoic Acid in a Triple Transgenic Mouse Model of Alzheimer's Disease: a 13C NMR Study

Overview

Journal J Cereb Blood Flow Metab

Publisher Sage Publications

Specialties Cardiology & Vascular Diseases
Endocrinology
Neurology

Date 2013 Nov 14

PMID 24220168

Citations 31

Authors

Harsh Sancheti

Keiko Kanamori

Ishan Patil

Roberta Diaz Brinton

Brian D Ross

Enrique Cadenas

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease is an age-related neurodegenerative disease characterized by deterioration of cognition and loss of memory. Several clinical studies have shown Alzheimer's disease to be associated with disturbances in glucose metabolism and the subsequent tricarboxylic acid (TCA) cycle-related metabolites like glutamate (Glu), glutamine (Gln), and N-acetylaspartate (NAA). These metabolites have been viewed as biomarkers by (a) assisting early diagnosis of Alzheimer's disease and (b) evaluating the efficacy of a treatment regimen. In this study, 13-month-old triple transgenic mice (a mouse model of Alzheimer's disease (3xTg-AD)) were given intravenous infusion of [1-(13)C]glucose followed by an ex vivo (13)C NMR to determine the concentrations of (13)C-labeled isotopomers of Glu, Gln, aspartate (Asp), GABA, myo-inositol, and NAA. Total ((12)C+(13)C) Glu, Gln, and Asp were quantified by high-performance liquid chromatography to calculate enrichment. Furthermore, we examined the effects of lipoic acid in modulating these metabolites, based on its previously established insulin mimetic effects. Total (13)C labeling and percent enrichment decreased by ∼50% in the 3xTg-AD mice. This hypometabolism was partially or completely restored by lipoic acid feeding. The ability of lipoic acid to restore glucose metabolism and subsequent TCA cycle-related metabolites further substantiates its role in overcoming the hypometabolic state inherent in early stages of Alzheimer's disease.

Citing Articles

Alpha-lipoic acid alleviates cognitive deficits in transgenic APP23/PS45 mice through a mitophagy-mediated increase in ADAM10 α-secretase cleavage of APP.

Zhang J, Jiang Y, Dong X, Meng Z, Ji L, Kang Y Alzheimers Res Ther. 2024; 16(1):160.

PMID: 39030577 PMC: 11264788. DOI: 10.1186/s13195-024-01527-3.

TgF344-AD Rat Model of Alzheimer's Disease: Spatial Disorientation and Asymmetry in Hemispheric Neurodegeneration.

Sagalajev B, Lennartz L, Vieth L, Gunawan C, Neumaier B, Drzezga A J Alzheimers Dis Rep. 2023; 7(1):1085-1094.

PMID: 37849636 PMC: 10578321. DOI: 10.3233/ADR-230038.

Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease.

Perluigi M, Di Domenico F, Butterfield D Physiol Rev. 2023; 104(1):103-197.

PMID: 37843394 PMC: 11281823. DOI: 10.1152/physrev.00030.2022.

Redox Imbalance in Neurological Disorders in Adults and Children.

Rey F, Berardo C, Maghraby E, Mauri A, Messa L, Esposito L Antioxidants (Basel). 2023; 12(4).

PMID: 37107340 PMC: 10135575. DOI: 10.3390/antiox12040965.

Mitochondria in health, disease, and aging.

Harrington J, Ryter S, Plataki M, Price D, Choi A Physiol Rev. 2023; 103(4):2349-2422.

PMID: 37021870 PMC: 10393386. DOI: 10.1152/physrev.00058.2021.

References

Tiwari V, Patel A . Impaired glutamatergic and GABAergic function at early age in AβPPswe-PS1dE9 mice: implications for Alzheimer's disease. J Alzheimers Dis. 2011; 28(4):765-9. DOI: 10.3233/JAD-2011-111502. View

Esteras N, Alquezar C, Bartolome F, Antequera D, Barrios L, Carro E . Systematic evaluation of magnetic resonance imaging and spectroscopy techniques for imaging a transgenic model of Alzheimer's disease (AβPP/PS1). J Alzheimers Dis. 2012; 30(2):337-53. DOI: 10.3233/JAD-2012-111967. View

Fitzpatrick S, Hetherington H, Behar K, Shulman R . The flux from glucose to glutamate in the rat brain in vivo as determined by 1H-observed, 13C-edited NMR spectroscopy. J Cereb Blood Flow Metab. 1990; 10(2):170-9. DOI: 10.1038/jcbfm.1990.32. View

Adalsteinsson E, Sullivan E, Kleinhans N, Spielman D, Pfefferbaum A . Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet. 2000; 355(9216):1696-7. DOI: 10.1016/s0140-6736(00)02246-7. View

Ori C, Dam M, Pizzolato G, Battistin L, Giron G . Effects of isoflurane anesthesia on local cerebral glucose utilization in the rat. Anesthesiology. 1986; 65(2):152-6. DOI: 10.1097/00000542-198608000-00004. View

Kanamori K, Ross B . The first in vivo observation of (13)C-(15)N coupling in mammalian brain. J Magn Reson. 2001; 153(2):193-202. DOI: 10.1006/jmre.2001.2432. View

Jessen F, Traeber F, Freymann K, Maier W, Schild H, Block W . Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology. 2006; 67(3):528-30. DOI: 10.1212/01.wnl.0000228218.68451.31. View

Farr S, Poon H, Dogrukol-Ak D, Drake J, Banks W, Eyerman E . The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem. 2003; 84(5):1173-83. DOI: 10.1046/j.1471-4159.2003.01580.x. View

Dedeoglu A, Choi J, Cormier K, Kowall N, Jenkins B . Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 2004; 1012(1-2):60-5. DOI: 10.1016/j.brainres.2004.02.079. View

10.

Schubert D . Glucose metabolism and Alzheimer's disease. Ageing Res Rev. 2005; 4(2):240-57. DOI: 10.1016/j.arr.2005.02.003. View

11.

Preece N, Cerdan S . Metabolic precursors and compartmentation of cerebral GABA in vigabatrin-treated rats. J Neurochem. 1996; 67(4):1718-25. DOI: 10.1046/j.1471-4159.1996.67041718.x. View

12.

Sibson N, Dhankhar A, MASON G, Rothman D, Behar K, Shulman R . Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci U S A. 1998; 95(1):316-21. PMC: 18211. DOI: 10.1073/pnas.95.1.316. View

13.

Anthony J, LeResche L, Niaz U, Von Korff M, Folstein M . Limits of the 'Mini-Mental State' as a screening test for dementia and delirium among hospital patients. Psychol Med. 1982; 12(2):397-408. DOI: 10.1017/s0033291700046730. View

14.

de la Monte S . Insulin resistance and Alzheimer's disease. BMB Rep. 2009; 42(8):475-81. PMC: 4600067. DOI: 10.5483/bmbrep.2009.42.8.475. View

15.

Hager K, Kenklies M, McAfoose J, Engel J, Munch G . Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. J Neural Transm Suppl. 2007; (72):189-93. DOI: 10.1007/978-3-211-73574-9_24. View

16.

Rupsingh R, Borrie M, Smith M, WELLS J, Bartha R . Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging. 2009; 32(5):802-10. DOI: 10.1016/j.neurobiolaging.2009.05.002. View

17.

Craft S . Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord. 2006; 20(4):298-301. DOI: 10.1097/01.wad.0000213866.86934.7e. View

18.

Packer L, Cadenas E . Lipoic acid: energy metabolism and redox regulation of transcription and cell signaling. J Clin Biochem Nutr. 2011; 48(1):26-32. PMC: 3022059. DOI: 10.3164/jcbn.11-005FR. View

19.

Yaworsky K, Somwar R, Ramlal T, Tritschler H, Klip A . Engagement of the insulin-sensitive pathway in the stimulation of glucose transport by alpha-lipoic acid in 3T3-L1 adipocytes. Diabetologia. 2000; 43(3):294-303. DOI: 10.1007/s001250050047. View

20.

Haris M, Nath K, Cai K, Singh A, Crescenzi R, Kogan F . Imaging of glutamate neurotransmitter alterations in Alzheimer's disease. NMR Biomed. 2012; 26(4):386-91. PMC: 3556355. DOI: 10.1002/nbm.2875. View